Status:
TERMINATED
Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery
Lead Sponsor:
Oslo University Hospital
Conditions:
Chronic Subdural Hematoma
Eligibility:
All Genders
55-100 years
Phase:
PHASE2
PHASE3
Brief Summary
Primary objectives of the study are to investigate whether adjuvant treatment in the form of Tranexamic acid (Cyklokapron) and Tocilizumab (RoAcmera) to surgery in patients with chronic subdural hemat...
Detailed Description
Primary endpoints in the study are: 1) determine postoperative recurrence requiring reoperation using clinical examination and CT imaging, 2) determine the time period necessary to complete healing us...
Eligibility Criteria
Inclusion
- patients with informed consent, without presenting of any known contraindication for the use of Tranexamic acid and Tocilizumab.
Exclusion
- patients or relatives who refused to consent, presenting of any known contraindication for the use of Tranexamic acid and Tocilizumab.
Key Trial Info
Start Date :
November 28 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2021
Estimated Enrollment :
382 Patients enrolled
Trial Details
Trial ID
NCT03353259
Start Date
November 28 2017
End Date
September 1 2021
Last Update
October 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Milo Stanisic
Oslo, Norway, 0424